Navigation Links
High-Dosage of Epirubicin and Cyclophosphamide may cause AML

Adjuvant chemotherapy with epirubicin and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome.

Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with higher than standard cumulative doses of epirubicin and cyclophosphamide have an increased risk of developing Acute myeloid leukemia (AML) or Myelodysplastic syndrome (MDS).

This study was done by Dr. David Rogers and his team, in which they have proved that patients undergoing adjuvant therapy with higher than standard cumulative doses of epirubicin and cyclophosphamide for early stage of breast cancer are at increased risk of developing AML or MDS. It has been reported that though the long-term survival of these patients as increased following administration of these drugs, but the risk of developing secondary AML with or without MDS has been increased.

Epirubicin monitoring plan was started by Dr. Rogers collaboration with Gruppo Pfizer of Milan, Italy to undergo 19 randomized clinical trials for adjuvant therapy in early breast cancer, the study included 9796 patients started in early 1984, with follow up till 2001. In this follow-up study 30 patients developed AML/MDS. Both the cumulative doses of epirubicin and cyclophosphamide had independent risk factors for AML/MDS. Other factors such as age, radiotherapy, granulocyte colony stimulating factor and tamoxifen were not independently associated with AML/MDS.

Patients taking more than the standard cumulative dose of epirubicin was found to have an increased relative risk of 6.80. The standard dose of epirubicin was found to be 720 mg/m. For doses no higher than the standard dose, "the low risk of secondary leukemia does not differ significantly from the risk in patients not treated with epirubicin or who received hormonal therapy only," Dr. Rogers' team notes.

Both epi rubicin and cyclophosphamide were usually administered in combination and the 4760 patients who received the standard doses of epirubicin and cyclophosphamide (6300 mg/m), the 8-year cumulative probability of developing AML/MDS was 0.37%, compared with 4.97% of the 261 patients who received higher cumulative doses of both drugs.

"In clinical practice, the described regimens have a strong benefit to risk ratio," the authors conclude, "and patients and clinicians can be reassured that the risk of leukemia is likely to be low if the cumulative doses of these regimens are not exceeded."
'"/>




Related medicine news :

1. Kissing can cause Kaposi’s Sarcoma in AID
2. Kidney Stones - Interesting New Research implicates bacteria as its cause
3. Roller coasters – cause “Chronic Headache?
4. Starvation in pregnant women can cause heart disease to their children
5. And now they say infections can cause heart disease!!!!
6. And now they say infections can cause heart disease!!!!
7. Ticks may cause more diseases
8. Depression may cause delayed wound healing
9. Analgesic abuse - cause for chronic headache in children
10. Strong pain killers likely to cause miscarriage
11. Pressure on spine cause problems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... , ... April 24, 2017 , ... My T Chai, ... its products are now available for purchase on RevNutrition.com, a popular website specializing in ... first produced and popularized in ancient India and Siam. It spread across Asia and ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... 24, 2017 , ... In 2017, up to 78,000 new ... of them will be malignant.(1) As research into precision medicine continues, both patients ... in the diagnosis and treatment of brain tumors. Healthcare facilities that are already ...
(Date:4/24/2017)... ... 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured ... at the forefront of Gardant since it was founded in 1999. His drive and ... of more than 40 new senior living communities. With his leadership, Gardant has grown ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: